SKB571

Phase 2Small molecule

SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

SKB571 is one of 123 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

122

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerNot yet recruiting

Non-Small Lung CancerRecruiting

Advanced Solid TumorsRecruiting

Lung CancerRecruiting

Pancreatic CancerPhase 2

Not yet recruiting

Non-Small Lung CancerPhase 2

Recruiting

Advanced Solid TumorsPhase 1

Recruiting

Lung CancerPhase 2

Recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

SKB571

SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 10

PD-1 Blocking Antibody

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Advanced Solid Tumors

NCT06725381

Q1 2028

Phase 2Recruiting

Lung Cancer

NCT07230405

Q2 2028

Phase 2Not yet recruiting

Pancreatic Cancer

NCT07814066

Q4 2028

Phase 2Recruiting

HNSCC

NCT07668154

Clinical

Trials by Indication[1]

Not yet recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07814066·30 enrolled

HNSCC1 trial

A Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB571 in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07668154·120 enrolled

Non-small Lung Cancer1 trial

A Phase II Clinical Study to Evaluate the Safety and Efficacy of SKB571 for Injection as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities

Recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07308106·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for SKB571. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SKB571 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SKB571. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

SKB571

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q2 2028

Q4 2028

Trials by Indication[1]

Advanced Solid Tumors1 trial

Lung Cancer1 trial

Pancreatic Cancer1 trial

HNSCC1 trial

Non-small Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News